Increase of human papillomavirus-16 E7-specific T helper type 1 response in peripheral blood of cervical cancer patients after radiotherapy.
It has been suggested that tumour cell lysis by gamma-radiation induces a tumoral antigen release eliciting an immune response. It is not clear how a specific immune response in cervical cancer patients is developed after radiotherapy. This study is an attempt to investigate the role of the human papillomavirus type 16 (HPV-16) E7-specific T helper response before and after radiotherapy. Lymphocytes were isolated from 32 cervical cancer patients before and after radiotherapy and from 16 healthy women. They were stimulated for 12 hr with autologous HPV-16 E7-pulsed monocyte-derived dendritic cells or directly with HPV-16 E7 synthetic peptides: E7(51-70), E7(65-84) and E7(79-98). The cells were stained for CD4, CD69, intracellular interferon-gamma (IFN-gamma) and interleukin-4 (IL-4) cytokines and analysed by flow cytometry. A specific CD4(+) CD69(+) IFN-gamma(+) immune response against HPV-16 E7(79-98) peptide was observed in 10 of 14 patients (71.4%) after treatment, compared with 4 of 14 (28.5%) before radiotherapy (P = 0.039); however, this response was not associated with a successful clinical response. Before treatment, 5 of 31 patients showed a HPV-16 E7(79-98)-specific T helper type 2 (Th2) response. Interestingly, this response was significantly associated with a decrease in disease-free survival (P = 0.027). These results suggest that a Th2-type cellular response could be useful as a predictor of recurrence and poor prognosis. An increase of the HPV-specific immune response was observed after radiotherapy; however, it is not enough to control completely the disease after treatment. Our results support that the E7-specific T-cell IFN-gamma response in cervical cancer patients, rather than reflecting the host's capability of controlling tumour growth, might be an indicator for disease severity.
Delgado
Félix Giovanni
FG
Grupo de Investigación en Biología del Cáncer, Instituto Nacional de Cancerología, Bogotá, Columbia.
Martínez
Elizabeth
E
Céspedes
María Angélica
MA
Bravo
María Mercedes
MM
Navas
María Cristina
MC
Cómbita Rojas
Alba Lucía
AL
D003713:Dendritic Cells / Q000276:immunology; D005260:Female; D005500:Follow-Up Studies; D015395:Histocompatibility Antigens Class I / Q000378:metabolism; D052162:Human papillomavirus 16 / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D016130:Immunophenotyping; D007371:Interferon-gamma / Q000096:biosynthesis; D015847:Interleukin-4 / Q000096:biosynthesis; D008213:Lymphocyte Activation / Q000276:immunology; D050725:Papillomavirus E7 Proteins / Q000276:immunology* / Q000378:metabolism; D030361:Papillomavirus Infections / Q000150:complications / Q000276:immunology*; D016019:Survival Analysis; D018417:Th1 Cells / Q000276:immunology*; D018418:Th2 Cells / Q000276:immunology; D002583:Uterine Cervical Neoplasms / Q000276:immunology* / Q000532:radiotherapy* / Q000821:virology
D015395:Histocompatibility Antigens Class I; D050725:Papillomavirus E7 Proteins; D015847:Interleukin-4; D007371:Interferon-gamma
EMBO J. 1987 Jan;6(1):139-44
3034571
Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12087-92
17615234
J Gen Virol. 1994 Sep;75 ( Pt 9):2277-84
8077925
Biochim Biophys Acta. 1996 Oct 9;1288(2):F55-78
8876633
J Clin Pathol. 2005 Oct;58(10):1096-100
16189158
Adv Immunol. 2000;75:235-82
10879286
Gynecol Oncol. 1990 Mar;36(3):435-8
2318457
J Virol. 1999 Jul;73(7):5402-10
10364287
Cancer Res. 1998 Apr 15;58(8):1700-6
9563486
Br J Cancer. 2005 Jul 25;93(2):248-59
15986031
J Gen Virol. 2003 May;84(Pt 5):1063-1070
12692269
Gynecol Oncol. 2000 Apr;77(1):116-20
10739700
Int J Cancer. 2002 Feb 20;97(6):796-803
11857357
Br J Cancer. 2002 Jul 29;87(3):324-33
12177803
Clin Exp Immunol. 2007 Nov;150(2):199-209
17937675
Gynecol Oncol. 2004 Aug;94(2):488-94
15297193
J Natl Cancer Inst. 1997 Feb 5;89(3):245-50
9017005
Int J Cancer. 2001 Dec 15;94(6):825-33
11745485
J Biomed Sci. 2000 Sep-Oct;7(5):341-56
10971133
Int J Cancer. 2006 May 15;118(10):2529-37
16353143
Cancer. 1998 Dec 1;83(11):2346-52
9840534
Arch Med Res. 1999 Jul-Aug;30(4):269-74
10573627
Cancer Res. 2004 Aug 1;64(15):5449-55
15289354
J Natl Cancer Inst. 1997 Sep 3;89(17):1285-93
9293919
Int J Cancer. 2005 Jan 10;113(2):276-83
15386416
J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S42-8
10430218
J Exp Med. 1994 Apr 1;179(4):1109-18
8145033
J Pathol. 1999 Sep;189(1):12-9
10451482
Vaccine. 2007 Feb 9;25(8):1379-89
17123670